David Schull

President of Russo Partners, a communications firm that works with innovators in healthcare and technology — and the home of the Sports-Health Alliance

[Russo Partners @russopartners]

When a high-stakes @US_FDA decision shifted unexpectedly, Russo Partners helped a client respond quickly with expert commentary that shaped early media narratives. The result: A @WSJ placement, broader syndication, and meaningful share of voice. https://t.co/L0w6XZXITt

[Lineage Cell Therapeutics @LineageCell]

We appreciate Dr. Joe Pantginis of @HCWCO for hosting a fireside chat with $LCTX ‘s @CEO_Culley as part of @HCWCO 4th Annual BioConnect Investor Conference at @NasdaqExchange.

Replay available here: https://t.co/m6UMmQas5j

#CellTherapy #InvestorRelations #ReplaceandRestore

[David Schull @davidschull]

Zacks Small Cap Research - FBLG: Phase 1/2 Trial of CYWC628 Underway https://t.co/Nfej2qzzhq

[David Schull @davidschull]

Natera, CytoDyn Partner in Colorectal Cancer Study | Contract Pharma https://t.co/flhDf4FVHS

[Coya Therapeutics @CoyaTx]

We’re honored to bat alongside former Yankees player @CDickerson_PFTP in raising awareness for people living with ALS.

Featured on the @Nasdaq Tower in Times Square, this message reflects a shared commitment to supporting the #ALS community and advancing the search for meaningful new treatment options.

Thank you to Chris for helping shine a spotlight on the urgent need for progress in ALS.

#NeurodegenerativeDisease #EndALS

[David Schull @davidschull]

A New Approach to Treating Respiratory Attacks | The Scientist https://t.co/ceSsAzOdpB

[David Schull @davidschull]

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer https://t.co/9PnSUkZS6g

[David Schull @davidschull]

Cocrystal Pharma names James Sapirstein as CEO | The Pharmaletter https://t.co/3wYC1EcNwU

[David Schull @davidschull]

Free event to celebrate students, raise asthma awareness in Las Vegas https://t.co/d7Y9uqDLvL

[David Schull @davidschull]

Cocrystal Pharma Appoints James Sapirstein, Biopharma https://t.co/uXssi3oqgD

[David Schull @davidschull]

FibroBiologics Announces First Patients Dosed in Phase 1/2 https://t.co/fsx7cW6Ooy

[David Schull @davidschull]

NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program - https://t.co/hnJKUPzZc6 https://t.co/3eiiX4KC3F

[David Schull @davidschull]

EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial - FibroBiologics (N - Benzinga https://t.co/ouVJ9Hl4bJ

[David Schull @davidschull]

NTRA & Diakonos partner to use Signatera in refractory melanoma trial https://t.co/FWQ3pM7H2Z

[David Schull @davidschull]

NeuroOne Reports 72 Percent Product Revenue Growth For OneRF System https://t.co/uZwyP8BnwX

[David Schull @davidschull]

The CFO helping to bring his biotech “to the finish line” https://t.co/Hk6hnFoNPb

[David Schull @davidschull]

@BioWorld @ApreaTX Great article and segment @russopartners

[FibroBiologics @FibroBiologics]

Stem cells dominate regenerative medicine.
But fibroblasts outnumber them 5,000 to 1.

$FBLG #Fibroblasts #Biotech #RegenerativeMedicine

[FibroBiologics @FibroBiologics]

.@FibroBiologics announced the first patients have been enrolled and dosed in the Phase 1/2 trial evaluating CYWC628 for diabetic foot ulcers. The prospective, multicenter, randomized study is being conducted across multiple sites in Australia and is designed to enroll up to 120 patients. The trial will evaluate the safety, tolerability, and efficacy of CYWC628, FibroBiologics’ investigational topically administered allogeneic fibroblast-spheroid cell-based therapy.

For more info, visit here: https://t.co/bfNoBzGziS

[David Schull @davidschull]

@CoyaTx @CDickerson_PFTP @alsnewstoday